Jinhe Biotechnology CO., LTD.
SZSE:002688.SZ
4.69 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,174.131 | 2,122.705 | 2,077.989 | 1,814.639 | 1,782.364 | 1,628.89 | 1,457.826 | 1,495.686 | 1,250.469 | 839.806 | 741.071 | 770.405 | 720.726 | 590.218 | 458.752 | 444.386 |
| Cost of Revenue
| 1,531.633 | 1,508.913 | 1,426.922 | 1,184.691 | 1,129.238 | 1,012.562 | 899.325 | 984.467 | 888.767 | 580.169 | 478.687 | 521.783 | 478.769 | 404.617 | 340.26 | 346.495 |
| Gross Profit
| 642.498 | 613.793 | 651.067 | 629.948 | 653.126 | 616.328 | 558.502 | 511.219 | 361.701 | 259.637 | 262.385 | 248.622 | 241.957 | 185.601 | 118.492 | 97.892 |
| Gross Profit Ratio
| 0.296 | 0.289 | 0.313 | 0.347 | 0.366 | 0.378 | 0.383 | 0.342 | 0.289 | 0.309 | 0.354 | 0.323 | 0.336 | 0.314 | 0.258 | 0.22 |
| Reseach & Development Expenses
| 74.003 | 82.285 | 72.251 | 66.358 | 60.703 | 40.512 | 33.526 | 11.31 | 5.68 | 4.203 | 3.392 | 1.896 | 0.931 | 1.011 | 0.706 | 0 |
| General & Administrative Expenses
| 84.055 | 57.759 | 57.305 | 59.269 | 52.529 | 58.209 | 50.64 | 45.141 | 35.981 | 23.65 | 19.302 | 26.363 | 21.564 | 22.522 | 13.396 | 36.974 |
| Selling & Marketing Expenses
| 143.364 | 130.717 | 122.505 | 113.21 | 129.561 | 131.787 | 113.491 | 96.876 | 68.979 | 54.775 | 57.865 | 46.865 | 40.938 | 35.918 | 28.282 | 19.717 |
| SG&A
| 227.42 | 188.475 | 179.81 | 172.479 | 182.089 | 189.995 | 164.131 | 142.017 | 104.959 | 78.425 | 77.167 | 73.228 | 62.503 | 58.439 | 41.678 | 56.691 |
| Other Expenses
| -73.975 | 171.003 | 168.072 | 159.814 | 153.248 | 135.604 | 127.975 | 9.408 | 7.611 | 11.057 | 2.53 | 9.123 | 4.284 | 2.646 | 0.42 | -0.382 |
| Operating Expenses
| 454.789 | 441.763 | 420.132 | 398.65 | 396.04 | 366.112 | 325.632 | 291.562 | 220.029 | 172.234 | 149.21 | 134.635 | 128.01 | 102.795 | 73.391 | 59.01 |
| Operating Income
| 104.733 | 205.024 | 225.511 | 218.19 | 318.865 | 271.849 | 204.363 | 209.206 | 120.919 | 83.412 | 106.776 | 99.082 | 87.334 | 61.541 | 31.743 | 18.494 |
| Operating Income Ratio
| 0.048 | 0.097 | 0.109 | 0.12 | 0.179 | 0.167 | 0.14 | 0.14 | 0.097 | 0.099 | 0.144 | 0.129 | 0.121 | 0.104 | 0.069 | 0.042 |
| Total Other Income Expenses Net
| -3.236 | -86.179 | -82.601 | -77.285 | -98.664 | -77.333 | -56.993 | -4.336 | -13.127 | 6.814 | -5.011 | -6.104 | -22.508 | -18.619 | -12.937 | -20.769 |
| Income Before Tax
| 101.496 | 118.845 | 142.911 | 140.905 | 220.201 | 194.516 | 147.37 | 215.321 | 128.545 | 94.217 | 108.164 | 107.883 | 91.439 | 64.187 | 32.163 | 18.113 |
| Income Before Tax Ratio
| 0.047 | 0.056 | 0.069 | 0.078 | 0.124 | 0.119 | 0.101 | 0.144 | 0.103 | 0.112 | 0.146 | 0.14 | 0.127 | 0.109 | 0.07 | 0.041 |
| Income Tax Expense
| 7.062 | 0.804 | 20.822 | 1.712 | 29.872 | 30.113 | 37.323 | 41.087 | 12.787 | 14.138 | 17.532 | 18.323 | 14.511 | 10.973 | 6.122 | 3.331 |
| Net Income
| 86.457 | 118.04 | 93.992 | 117.325 | 184.939 | 163.629 | 108.424 | 164.129 | 104.653 | 77.21 | 90.432 | 89.577 | 77.405 | 52.754 | 27.028 | 15.87 |
| Net Income Ratio
| 0.04 | 0.056 | 0.045 | 0.065 | 0.104 | 0.1 | 0.074 | 0.11 | 0.084 | 0.092 | 0.122 | 0.116 | 0.107 | 0.089 | 0.059 | 0.036 |
| EPS
| 0.11 | 0.15 | 0.14 | 0.18 | 0.29 | 0.26 | 0.17 | 0.26 | 0.19 | 0.14 | 0.17 | 0.19 | 0.19 | 0.13 | 0.066 | 0.039 |
| EPS Diluted
| 0.11 | 0.15 | 0.14 | 0.18 | 0.29 | 0.26 | 0.17 | 0.26 | 0.19 | 0.14 | 0.17 | 0.19 | 0.19 | 0.13 | 0.066 | 0.039 |
| EBITDA
| 305.172 | 360.919 | 357.589 | 338.144 | 418.311 | 358.179 | 276.78 | 310.56 | 213.816 | 143.413 | 152.988 | 163.982 | 153.412 | 117.627 | 77.194 | 39.602 |
| EBITDA Ratio
| 0.14 | 0.17 | 0.172 | 0.186 | 0.235 | 0.22 | 0.19 | 0.208 | 0.171 | 0.171 | 0.206 | 0.213 | 0.213 | 0.199 | 0.168 | 0.089 |